Navigation Links
Phase III studies show linagliptin improved blood glucose control in Asian adults with type 2 diabetes
Date:6/22/2013

RIDGEFIELD, Conn. and INDIANAPOLIS, June 22, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results from two phase III clinical studies that showed linagliptin in Asian adults, as monotherapy and in combination with metformin, improved blood glucose control in people with type 2 diabetes (T2D) from China, Malaysia and the Philippines. The study data from two randomized phase III clinical trials were presented at the American Diabetes Association 73rd Scientific Sessions®.

In Asia, the rate of T2D is rapidly increasing. If the current trend continues, it is estimated that more than 60 percent of the world's diabetes population will be in Asia by 2030.1 Similarly, in the United States, the rate of T2D in Chinese Americans is much higher than the rate in the Chinese population living in rural China.2 A combination of both genetic and environmental influences is attributed to the higher rate of T2D in people of Asian descent.2

"The results of these two studies continue to support use of linagliptin in Asian adults with type 2 diabetes," said Christophe Arbet-Engels, MD, PhD, MBA, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "Adults of Asian descent with type 2 diabetes tend to develop the condition at a younger age than those from Western populations, regardless of their body weight." 1

In the first study, linagliptin monotherapy demonstrated a 0.68 percent reduction in HbA1c (from a mean baseline H
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... und TÜBINGEN, Deutschland, 5. März 2015 /PRNewswire/ ... und das deutsche biopharmazeutische Unternehmen CureVac geben ... Euro (52 Millionen US-Dollar) in CureVac investiert. ... medizinisch angewandten Messenger-RNA (mRNA). Auf Basis dieses ... Behandlung von Krankheiten und zum Schutz vor ...
(Date:3/5/2015)... 2015  BioPhotas, Inc., an FDA registered medical device ... technologies to treat skin, muscle and joint conditions, today ... Fund to provide BioPhotas, flagship product, the Celluma, ... solutions.  Commenting on the alliance, ... the Celluma at the Warrior Hope and Care Center ...
(Date:3/5/2015)... -- Sanomedics, Inc. (OTC: SIMH, SIMHD) ("Sanomedics" or the "Company"), ... and acquiring cutting-edge technology, products and services announced today ... at booth # 709 at the National Association ... on March 11-13, 2015 at Caesars Palace in ... The 36 th annual NAPNAP Conference will bring ...
Breaking Medicine Technology:Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 4BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 2Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 3
... April 8, 2011 ImageXpres Corporation (Pink Sheets: ... financial results and annual report that highlighted the key ... 31, 2010. Overall financial results for 2010 demonstrated significant ... and net income of $109,033 for all of 2010, ...
... 8, 2011 Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ... of drugs for the treatment of human viral diseases, today ... 18,310,000 shares of its common stock at a public offering ... being sold by Idenix. The offering is expected to close ...
Cached Medicine Technology:ImageXpres Posts OTC Markets 2010 Annual Report 2ImageXpres Posts OTC Markets 2010 Annual Report 3Idenix Pharmaceuticals Prices Public Offering of Common Stock 2
(Date:3/6/2015)... OR (PRWEB) March 06, 2015 Ticket Down ... in Portland, Oregon at the Moda Center. After ... superstar Garth Brooks is showing no signs of letting up ... the country legend and his wife, Trisha Yearwood, to venues ... would be bringing their critically acclaimed tour to the Moda ...
(Date:3/6/2015)... March 06, 2015 Ticket Down is a ... popular ticket exchange has extended their customer appreciation discount code ... Bridge, West Yorkshire England and he began his career in ... the past couple of years Ed Sheeran has become a ... Sheeran is on stage he is having the time of ...
(Date:3/6/2015)... At Natural Products Expo West, Makeena, ... of its powerful, location-aware iOS app that helps ... at any retailer that carries those products, including ... Booth 6054. , Makeena’s proprietary algorithm allows ... Paleo, and vegan, among many other product attributes. ...
(Date:3/6/2015)... Many patients with knee osteoarthritis have continued ... (or someone you know) have chronic pain and problems ... interested in the ACT-OA clinical trial. , Kevin ... is one of fifteen physicians in the U.S. to ... as part of a new, multi-site, double blind, placebo-controlled ...
(Date:3/6/2015)... Raleigh, NC (PRWEB) March 06, 2015 In ... percentage of Polish mesothelioma patients reported that shoulder pain was ... full story on its website. Click here to read ... in Warsaw analyzed the medical records of 49 mesothelioma ... of them reported that it was shoulder pain that first ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:Ed Sheeran Tickets in Indianapolis, Austin, Albany, St. Louis, London, Des Moines, Salt Lake City, Saskatoon, Regina and Denver/Morrison Now On Sale at Ticket Down 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Kevin Darr, M.D. is Now Enrolling Patients in a New FDA-Approved Clinical Trial Evaluating Adipose-Derived Regenerative Cells in the Treatment of Knee Osteoarthritis 2Health News:New Report Reveals Shoulder Pain Could Signal Early Mesothelioma, According to Surviving Mesothelioma 2
... In a study, U.S. researchers have found an increase in the ... the last 50 years//. Girls lose their virginity at the age ... to 15 for which the reasons may be less guilt about ... ,The study done by Jean Twenge, associate professor in psychology at ...
... recent survey it was found that people who were in ... look//. This resulted in an increase in the rates of ... in creating awareness among the procedures used in these surgeries. ... in the number of men and women in their sixties ...
... hundreds of people suffering from gastroenteritis have been admitted in ... reported Monday. ,At least three children have died of ... deaths were reported from southern Punjab, as temperatures shot up ... Dera Ghazi Khan and Bahawalpur. ,More than 150 ...
... over 4,000 people dying in road traffic accidents in the ... senior Delhi Police official. , ,"This city has a ... difficult to control and coordinate the traffic if the standard ... joint commissioner, traffic, said. ,He also said that about ...
... colleges in Delhi went on mass casual leave ... but compounding// the sufferings of patients. ,The ... College (MAMC), University College of Medical Sciences (UCMS) ... express their resentment against the government decision to ...
... 3 years woke up after being administered a sleeping pill, ... hit the research table for thorough clinical testing. , ... tested on 30 patients during the course of this year, ... of coma. After the initial success, the pill has been ...
Cached Medicine News:Health News:Road Traffic Accidents Kill 4,000 people in Delhi 2Health News:Mass Leave By Doctors Leaves Patients Helpless 2
Poly stat Strep A is a lateral flow, one-step immunoassay for the rapid, qualitative detection of Group A Streptococcal antigen from throat swabs. The test is intended for use as an aid in the diagn...
... The CoaguChek S System offers ... in just one minute requiring only ... enable you to provide more comprehensive ... with each patient. The CoaguChek S ...
The QuickScreen Pro Multi Drug Screening Test is a rapid, self-timing, qualitative immunoassay for,the detection of drugs of abuse in urine....
The Osteomark NTx Point of Care (POC)device allows physicians to monitor their patients response to anti-resorptive drugs as early as 3-6 months from starting treatment. Osteomark NTx shows you and y...
Medicine Products: